Flagship Ventures Fund Iv-rx, L.p. - Net Worth and Insider Trading
Flagship Ventures Fund Iv-rx, L.p. Net Worth
The estimated net worth of Flagship Ventures Fund Iv-rx, L.p. is at least $2 Million dollars as of 2024-06-07. Flagship Ventures Fund Iv-rx, L.p. is the 10% Owner of Syros Pharmaceuticals Inc and owns about 480,666 shares of Syros Pharmaceuticals Inc (SYRS) stock worth over $2 Million. Details can be seen in Flagship Ventures Fund Iv-rx, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Flagship Ventures Fund Iv-rx, L.p. has not made any transactions after 2016-07-06 and currently still holds the listed stock(s).
Transaction Summary of Flagship Ventures Fund Iv-rx, L.p.
Flagship Ventures Fund Iv-rx, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Flagship Ventures Fund Iv-rx, L.p. owns 9 companies in total, including Moderna Inc (MRNA) , Evelo Biosciences Inc (EVLO) , and Axcella Health Inc (AXLA) among others .
Insider Ownership Summary of Flagship Ventures Fund Iv-rx, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MRNA | Moderna Inc | 2018-12-07 | 10 percent owner |
| EVLO | Evelo Biosciences Inc | 2018-05-08 | 10 percent owner |
| AXLA | Axcella Health Inc | 2020-05-18 | 10 percent owner |
 | | 2018-07-17 | 10 percent owner |
| | 2017-08-17 | 10 percent owner |
| | 2016-09-06 | 10 percent owner |
| | 2016-08-11 | 10 percent owner |
| | 2020-11-23 | 10 percent owner |
| | 2016-09-06 | 10 percent owner |
Flagship Ventures Fund Iv-rx, L.p. Latest Holdings Summary
Flagship Ventures Fund Iv-rx, L.p. currently owns a total of 1 stock. Flagship Ventures Fund Iv-rx, L.p. owns 480,666 shares of Syros Pharmaceuticals Inc (SYRS) as of July 6, 2016, with a value of $2 Million.
Latest Holdings of Flagship Ventures Fund Iv-rx, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SYRS | Syros Pharmaceuticals Inc | 2016-07-06 | 480,666 | 5.05 | 2,427,363 |
Holding Weightings of Flagship Ventures Fund Iv-rx, L.p.
Flagship Ventures Fund Iv-rx, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Flagship Ventures Fund Iv-rx, L.p. has made a total of 0 transactions in Syros Pharmaceuticals Inc (SYRS) over the past 5 years. The most-recent trade in Syros Pharmaceuticals Inc is the acquisition of 40,000 shares on July 6, 2016, which cost Flagship Ventures Fund Iv-rx, L.p. around $5 Million.
Insider Trading History of Flagship Ventures Fund Iv-rx, L.p.
- 1
Flagship Ventures Fund Iv-rx, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Flagship Ventures Fund Iv-rx, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Flagship Ventures Fund Iv-rx, L.p. is -20.83%. GuruFocus also compares Flagship Ventures Fund Iv-rx, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Flagship Ventures Fund Iv-rx, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Flagship Ventures Fund Iv-rx, L.p.'s insider trading performs compared to the benchmark.
Performance of Flagship Ventures Fund Iv-rx, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -43.61 | | | | | |
| Relative Return to S&P 500(%) | -47.57 | | | | | |
Flagship Ventures Fund Iv-rx, L.p. Ownership Network
Flagship Ventures Fund Iv-rx, L.p. Owned Company Details
What does Moderna Inc do?
Who are the key executives at Moderna Inc?
Flagship Ventures Fund Iv-rx, L.p. is the 10 percent owner of Moderna Inc. Other key executives at Moderna Inc include Chief Financial Officer James M Mock , Chief Legal Officer Shannon Thyme Klinger , and President Stephen Hoge .
Moderna Inc (MRNA) Insider Trades Summary
Over the past 18 months, Flagship Ventures Fund Iv-rx, L.p. made no insider transaction in Moderna Inc (MRNA). Other recent insider transactions involving Moderna Inc (MRNA) include a net sale of 590,000 shares made by Noubar Afeyan , a net sale of 2,253,506 shares made by Stephane Bancel , and a net sale of 170,636 shares made by Stephen Hoge .
In summary, during the past 3 months, insiders sold 220,307 shares of Moderna Inc (MRNA) in total and bought 0 shares, with a net sale of 220,307 shares. During the past 18 months, 3,035,404 shares of Moderna Inc (MRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,035,404 shares.
Moderna Inc (MRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Moderna Inc Insider Transactions
Flagship Ventures Fund Iv-rx, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Flagship Ventures Fund Iv-rx, L.p.. You might contact Flagship Ventures Fund Iv-rx, L.p. via mailing address: 55 Cambridge Parkway, 8th Floor, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
